Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clarithromycin-resistant Mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice
Autore:
Bermudez, LE; Nash, K; Petrofsky, M; Young, LS; Inderlied, CB;
Indirizzi:
Calif Pacific Med Ctr, Kuzell Inst Arthrit & Infect Dis, San Francisco, CA94115 USA Calif Pacific Med Ctr San Francisco CA USA 94115 n Francisco, CA94115 USA Univ So Calif, Los Angeles, CA USA Univ So Calif Los Angeles CA USAUniv So Calif, Los Angeles, CA USA Childrens Hosp, Los Angeles, CA 90027 USA Childrens Hosp Los Angeles CA USA 90027 s Hosp, Los Angeles, CA 90027 USA
Titolo Testata:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
fascicolo: 10, volume: 44, anno: 2000,
pagine: 2619 - 2622
SICI:
0066-4804(200010)44:10<2619:CMAISS>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMPLEX BACTEREMIA; ETHAMBUTOL; AIDS; INTRACELLULARE; AZITHROMYCIN; COMBINATION; PROPHYLAXIS; RIFABUTIN; INFECTION; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Bermudez, LE Calif Pacific Med Ctr, Kuzell Inst Arthrit & Infect Dis, Webster St,Suite 305, San Francisco, CA 94115 USA Calif Pacific Med Ctr WebsterSt,Suite 305 San Francisco CA USA 94115
Citazione:
L.E. Bermudez et al., "Clarithromycin-resistant Mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice", ANTIM AG CH, 44(10), 2000, pp. 2619-2622

Abstract

Resistance to clarithromycin in breakthrough Mycobacterium avium complex (MAC) isolates typically occurs 3 to 4 months after the initiation of monotherapy in bacteremic AIDS patients, It has been suggested that continuation of clarithromycin therapy still results in clinical and microbiological improvement. To study this paradox, C57BL/6 beige mice were infected with a clarithromycin-resistant (MIC, greater than or equal to 128 mu g/ml) strain of MAC 101 (CLA-R MAC 101) and treated with 200 mg of clarithromycin per kg of body weight/day alone or in combination with ethambutol (100 mg/kg/day) for 2 weeks. Mice infected with a clarithromycin-susceptible strain of MAC 101 had bacterial loads reduced by 90% in the liver and 91% in the spleen (P < 0.05, compared with the control). Clarithromycin treatment of CLA-R MAC101 resulted in a 65% reduction of bacterial loads in the liver (P = 0.009) and a 71% reduction in the spleen (P = 0.009), compared with the results for the untreated control. CLA-R MAC 101 and MAC 101 (isogenic strains) hadcomparable growth rates in murine tissue, ruling out a loss of virulence of CLA-R MAC 101. Strains of MAC currently defined as macrolide resistant may still respond to treatment with an agent such as clarithromycin within infected tissues.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 09:13:03